CrystalGenomics Invites Co (XKRX:083790) Debt-to-Equity : 0.23 (As of Mar. 2024)

View and export this data going back to 2006. Start your Free Trial

What is CrystalGenomics Invites Co Debt-to-Equity?

CrystalGenomics Invites Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩3,067.9 Mil. CrystalGenomics Invites Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩28,921.8 Mil. CrystalGenomics Invites Co's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ₩137,373.0 Mil. CrystalGenomics Invites Co's debt to equity for the quarter that ended in Mar. 2024 was 0.23.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for CrystalGenomics Invites Co's Debt-to-Equity or its related term are showing as below:

XKRX:083790' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.12 Med: 0.37 Max: 1.01
Current: 0.23

During the past 13 years, the highest Debt-to-Equity Ratio of CrystalGenomics Invites Co was 1.01. The lowest was 0.12. And the median was 0.37.

XKRX:083790's Debt-to-Equity is ranked worse than
58.98% of 1058 companies
in the Biotechnology industry
Industry Median: 0.14 vs XKRX:083790: 0.23

CrystalGenomics Invites Co Debt-to-Equity Historical Data

The historical data trend for CrystalGenomics Invites Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CrystalGenomics Invites Co Debt-to-Equity Chart

CrystalGenomics Invites Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.62

0.29

0.36

0.37

0.22

CrystalGenomics Invites Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.49	0.48	0.42	0.22	0.23

Competitive Comparison of CrystalGenomics Invites Co's Debt-to-Equity

For the Biotechnology subindustry, CrystalGenomics Invites Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CrystalGenomics Invites Co's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CrystalGenomics Invites Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where CrystalGenomics Invites Co's Debt-to-Equity falls into.

CrystalGenomics Invites Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

CrystalGenomics Invites Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2113.879	+	29889.276)	/	145292.993
	=	0.22

CrystalGenomics Invites Co's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3067.926	+	28921.755)	/	137372.976
	=	0.23

CrystalGenomics Invites Co (XKRX:083790) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

CrystalGenomics Invites Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of CrystalGenomics Invites Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

CrystalGenomics Invites Co (XKRX:083790) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CrystalGenomics Invites Co Ltd (XKRX:083790) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

5F, A-dong, Korea Bio Park, 694-1, Sampyeong-dong, Bundang-gu, Seongnam-si, Gyeonggi, KOR, 463-400

Website

http://www.crystalgenomics.com

CrystalGenomics Invites Co Ltd Formerly CrystalGenomics Inc is one of the leading biopharmaceutical company in Korea. The company is mainly engaged in the research and development and new drug development. It develops innovative new drug development projects such as eradication antibiotics and molecular targeted anticancer drugs. It focuses on arthritic medicines and antibiotics which kill resistant bacteria. It also offers medicines for cancer, obesity, asthma, and diabetes.

CrystalGenomics Invites Co (XKRX:083790) Headlines

No Headlines